JPRN-UMIN000001050已完成2 期
A phase II study of the combination of Rituximab, Mitoxantrone, Etoposide, and Prednisolone for relapsed elderly patients with diffuse large B-cell lymphoma (R-MEP07) - A phase II study of the combination of Rituximab, Mitoxantrone, Etoposide, and Prednisolone for relapsed elderly patients with lymphoma (R-MEP07)
Clinical Hematology Study Group of National Hospital Organization (CHSG-NHO)0 个研究点目标入组 40 人开始时间: 2008年3月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 70years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) CNS involvement 2) History of glaucoma 3) History of severe drug allergy 4) Active infectious diseases 5) HIV or HTLV-1 positive 6) HBs antigen or HCV antibody positive 7) Significant complications which include cardiac dysfunction, liver cirrhosis, uncontrolled diabetes, renal failure 8) Interstitial pneumonitis or fibrosis 9) History of other active malignancy 10) Severe mental disorder 11) Regular use of systemic steroids 12) Inadequate physical condition, as diagnosed by primary physician
研究者
相似试验
未知
2 期
Japanese Phase II Study of Rituximab in combination with FC-chemotherapy in patients with previously untreated Chronic Lymphocytic LeukemiaJPRN-jRCT2080222236ZENYAKU KOGYO CO., LTD.6
已完成
不适用
Phase II study of Rituximab in Patients with Systemic Lupus ErythematosusSystemic lupus erythematosusJPRN-UMIN000000762Zenyaku Kogyo Co., Ltd.70
进行中（未招募）
1 期
Study of Rituximab and Ibrutinib (RI) versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as initial therapy for Waldenström's macroglobulinaemiaWaldenström's macroglobulinaemiaEUCTR2019-001261-33-GBniversity College London148
进行中（未招募）
1 期
Multicenter study of phase II with Rituximab, cyclophosphamide, doxorubicin liposomal (Myocet), vincristine, Prednisone, (R-COMP) in diffuse Non-Hodgkin`s lymphoma, large B cells of the cardiopathic patient - HEART01Diffuse Non-Hodgkin`s lymphoma, large B cells of the cardiopathic patientMedDRA version: 9.1Level: PTClassification code 10012818EUCTR2009-012143-42-ITIIL INTERGRUPPO ITALIANO LINFOMI ONLUS50
进行中（未招募）
1 期
Evaluation of Rituximab-based Regimen Compared to Conventional Therapeutic Strategy For Remission Induction In Patients With Newly-Diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. Prospective, randomized, controlled, double-blind study. - REOVASEUCTR2016-000275-25-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)108